<p>Because of the abortifacient property of the Misoprostol component, it is contraindicated in women who are pregnant. It should not be used in women of childbearing potential unless the patient requires nonsteroidal anti-inflammatory drug (NSAID) therapy and is at high risk of developing gastric or duodenal ulceration or for developing complications from gastric or duodenal ulcers associated with the use of the NSAID. In such patients, it may be prescribed if the patient:</p>

<ul>
	<li>has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.</li>
	<li>is capable of complying with effective contraceptive measures.</li>
	<li>has received both oral and written warnings of the hazards of Misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.</li>
	<li>will begin it only on the second or third day of the next normal menstrual period.</li>
</ul>

<p>Excretion of the active metabolite (Misoprostol acid) into milk is possible but has not been studied. Because of the potential for serious adverse reactions in nursing infants, it is not recommended for use by nursing mothers.</p>